Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Nitroarginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.52 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.49 |
| ▸ | NOS1 | P29475 | 6/20 | 0.46 |
| ▸ | NOS2 | P35228 | 5/20 | 0.41 |
| ▸ | NOS3 | P29474 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitroarginine SCHEMBL8527873 | 0.94 | DDAH1 (0.53) | OTCDDAH1NOS1NOS2NOS3 | |
| Nitroarginine SCHEMBL12556124 | 0.94 | DDAH1 (0.53) | OTCDDAH1NOS1NOS2NOS3 | |
| Nitroarginine SCHEMBL8527851 | 0.94 | DDAH1 (0.53) | OTCDDAH1NOS1NOS2NOS3 | |
| Nitroarginine SCHEMBL14220319 | 0.94 | DDAH1 (0.53) | OTCDDAH1NOS1NOS2NOS3 | |
| L-Name SCHEMBL6054203 | 0.86 | NOS1 (0.38) | OTCDDAH1NOS1TSHR | |
| L-Name SCHEMBL29362113 | 0.80 | NOS1 (0.41) | OTCDDAH1NOS1TSHR | |
| L-Name SCHEMBL5966636 | 0.80 | NOS1 (0.41) | OTCDDAH1NOS1TSHR | |
| SCHEMBL12556111 | 0.79 | NOS1 (0.46) | OTCDDAH1NOS1NOS2NOS3 | |
| Hydrochloric Acid SCHEMBL7365158 | 0.78 | DDAH1 (0.38) | OTCDDAH1NOS1NOS2NOS3 | |
| SCHEMBL14350781 | 0.78 | NOS1 (0.40) | OTCDDAH1NOS1NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105501-B2 | Salt compositions for inhibition of the formation of new vaculature by angiogenesis | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2006-09-12 | — | — | US | claimed |
| EP-1311514-B1 | COMPOSITIONS WITH VASCULAR DAMAGING ACTIVITY | ANGIOGENE PHARM LTD (GB) | 2005-01-26 | — | — | EP | claimed |
| US-20030181424-A1 | Compositions with vascular damaging activity | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2003-09-25 | — | — | US | claimed |
| EP-1311514-A1 | COMPOSITIONS WITH VASCULAR DAMAGING ACTIVITY | Angiogene Pharmaceuticals Limited (GB) | 2003-05-21 | — | — | EP | claimed |
| WO-2002014329-A1 | COMPOSITIONS WITH VASCULAR DAMAGING ACTIVITY | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2002-02-21 | — | — | WO | claimed |
| US-7105501-B2 | Salt compositions for inhibition of the formation of new vaculature by angiogenesis | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2006-09-12 | — | — | US | disclosed |
| EP-1311514-B1 | COMPOSITIONS WITH VASCULAR DAMAGING ACTIVITY | ANGIOGENE PHARM LTD (GB) | 2005-01-26 | — | — | EP | disclosed |
| US-20030181424-A1 | Compositions with vascular damaging activity | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181424-A1 | Compositions with vascular damaging activity | VEGFA, ACIN1, BCL2L13 | OTC 4770/4885DDAH1 2160/4885NOS1 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.